Australia's most trusted
source of pharma news
Tuesday, 23 April 2024
Posted 8 August 2022 AM
Registrations of prescription medicines hit a record low for 2022 last week, with only one generic approved by the TGA.
Baxter Healthcare became the thirteenth company to add a copy of Janssen's PBS-listed blood cancer drug Velcade. The regulator approved Baxter's 3.5 mg strength under the brand name Bortezomib Baxter.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.